Aurinia Pharmaceuticals Inc., of Victoria, British Columbia, reported top-line results from its phase IIb AURA-LV study in lupus nephritis, showing that, at 48 weeks, the trial met the complete remission (CR) and partial remission (PR) endpoints, demonstrating statistically significantly greater CR and PR in patients in both low-dose (23.7 mg of voclosporin twice daily [p